Pivot Bio
Pivot Bio makes gene-edited microbes that replace synthetic nitrogen fertilizer for corn and other row crops.
On the record
Checkpoint: PROVEN G3 state registrations complete and commercial launch
The call
Pivot Bio has real patents, dealers, and retention numbers, but its valuation has fallen sharply and its next product launch and financing round will decide what happens next.
Pivot Bio sells specially engineered microbes that reduce how much fertilizer farmers need to buy, and they have sold over $100 million worth and signed up more than 700 dealers. The problem is that big fertilizer and seed companies like Corteva, Bayer, and Syngenta are not blocked from building the same thing themselves, and Corteva already bought a competitor called Symborg for $370 million to do exactly that. What happens next depends on whether Pivot Bio can launch and sell its new PROVEN G3 product successfully in 2026, and whether they can raise money before that, because their stock value has dropped sharply from its peak.
Why
01
AI pressure: None apparent. No AI product fixes nitrogen in soil; ag-AI tools optimize fertilizer timing but don't replace the microbe itself. Could AI do the core job? Unlikely.
02
Bigger players: Corteva Agriscience (via Symborg acquisition, 2022). Corteva bought a nitrogen-fixing biological and could bundle it into its Pioneer seed channel, but hasn't shipped that combo yet. Could a giant copy it? Yes, easily.
03
What protects it. 60 granted patents plus 250+ pending, a 700+ dealer network, and >190% retention from early grower cohorts.
What would change this call
Corteva bundles a Symborg-derived biological into its Pioneer seed channel within 18 months. Would show an incumbent using distribution scale to intercept Pivot Bio's grower base.
Pivot Bio's PROVEN G3 completes state registrations and ships on schedule in 2026. Would show the company's next-gen product moat holding up against incumbent competition.
A priced funding round or IPO filing that resolves the gap between the ~$500M secondary and prior $2B valuation. Would show whether investor confidence is recovering or eroding further.
Pivot Bio's PROVEN G3 completes state registrations and ships on schedule in 2026. Would show the company's next-gen product moat holding up against incumbent competition.
A priced funding round or IPO filing that resolves the gap between the ~$500M secondary and prior $2B valuation. Would show whether investor confidence is recovering or eroding further.
Key numbers
- $100M+ revenue in FY2023, up 60%+ year-over-year
- 700+ resellers; top 200 drove >80% of 2025 growth
- 60 granted patents, 250+ pending as of Jan 2025
Named risks
- Valuation gap: ~$500M secondary estimate vs $2B last priced round could trigger a down-round.
- PROVEN G3 launch depends on pending 2026 state registrations, delay would hit revenue growth.
- Incumbents (Corteva, Syngenta, Bayer) acquiring biologicals and bundling into existing seed distribution channels.
- PROVEN only replaces up to 40 of 150-200 lbs/acre nitrogen needed, limiting product's total addressable value versus synthetic fertilizer.
- No revenue figures confirmed since FY2023; progress toward $1B/2030 target is unverified company claim.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Corteva Agriscience | losing to | Acquired nitrogen-fixing biological Symborg for ~$370M in 2022, entering market via M&A |
| Syngenta | contesting | Acquired Intrinsyx Bio for $79M, per 2025-09-09 industry analysis |
| Bayer/Joyn Bio | contesting | Bayer-Ginkgo Bioworks JV targeting nitrogen fixation, noted as well-resourced pre-commercial player in 2021 |
| Microsoft AgPilot | gaining on | General-purpose agronomy AI tool launched May 2024 could commoditize Pivot's Agronomy Co-Pilot advisory layer |
| Kula Bio, Sound Agriculture, BioConsortia | contesting | Well-funded microbial nitrogen peers raising $70M-$150M+ each as of Sept 2025 |
Questions people ask
- Is Pivot Bio profitable in 2026?
- No profitability figures are public. Pivot Bio reported $100M+ revenue for FY2023 (Aug 2023) and set a target of $1B annual revenue by 2030 announced at its July 2025 Investor Day, but no profit/loss data has been disclosed.
- Did Pivot Bio have layoffs?
- Yes. A WARN notice filed May 2025 disclosed Pivot Bio laid off 62 workers in Berkeley, California, effective July 21, 2025, coinciding with its relocation of operations away from the Bay Area.
- Who owns Pivot Bio?
- Pivot Bio is privately held and venture-backed with no parent company or IPO filed as of November 2023. Investors include DCVC, Temasek, Continental Grain, Bunge Ventures, and Bayer, among roughly 23-25 total investors as of July 2021.
- Could AI replace Pivot Bio's product?
- No. Pivot Bio's core value is a physical, gene-edited living microbial product with 60 granted patents as of January 2025, field-validated and regulated. AI only touches a peripheral advisory tool, Agronomy Co-Pilot, launched July 2025, which faces competition from Microsoft AgPilot.
- Who is Pivot Bio's biggest competitor?
- Corteva Agriscience is the most significant threat, having acquired nitrogen-fixing biological company Symborg for about $370 million in 2022, giving a seed/crop-protection major direct entry into Pivot Bio's market via M&A rather than internal R&D.
- Is Pivot Bio's valuation falling?
- Secondary-market tracker TrueUp estimated Pivot Bio's valuation at roughly $500 million as of mid-2026, a steep discount from the $2 billion valuation set in its $430 million Series D round closed July 2021 led by DCVC and Temasek.
Timeline
- 2026-06-09Pivot Bio announces additions to senior management in finance and corporate development
- 2026-04-28Pivot Bio expands St. Louis footprint with new manufacturing centers of excellence
- 2026-03-31Pivot Bio launches multiyear nitrogen price and supply assurance program for 2026-2028
- 2026-03-04Pivot Bio relocates global HQ from California to Minnetonka, Minnesota
- 2025-07-28Inaugural Investor Day: sets $1B revenue by 2030 target, launches Agronomy Co-Pilot
- 2025-07-21Layoff of 62 workers at Berkeley, California office takes effect
- 2025-05-30Pivot Bio unveils PROVEN G3, third-generation nitrogen product pending state registrations
- 2025-01-30Company reports 60 granted patents and 250+ pending, peer-reviewed efficacy study published
- 2023-08-29Chris Abbott named CEO; company reports surpassing $100M FY2023 revenue
- 2021-07-18Closes $430M Series D led by DCVC and Temasek at roughly $2B valuation
Revision history
25 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Pivot Bio blazes past $100m revenue mark, appoints a new CEO (2023-08-29)
- Pivot Bio Stock Price, Funding, Valuation, Revenue & Financial Statements (2021-07-18)
- Pivot Bio Company Profile (2026-06-30)
- Upstream Ag Professional (2025-07-28)
- Pivot Bio Investor Day Highlights and Analysis (2025-07-28)
- Pivot Bio Unveils PROVEN G3 (2025-05-30)
- Pivot Bio Relocates Global Headquarters to Minnesota (2026-03-04)
- Pivot Bio, Inc. Lays Off 62 Workers, Berkeley, CA WARN Notice July 2025 (2025-07-20)
- Peer-Reviewed Study Validates Pivot Bio's Gene-Edited Microbes (2025-01-30)
- Crop Agnostic Nitrogen Fixing Technology (2025-09-09)
- 4 Companies Replacing Nitrogen in Fertilizers (2021-07-11)
- Pivot Bio Names Chris Abbott CEO (2023-08-29)